
- Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume of 8.06 million shares, closed regular trading session at $74.86.
- Rani Therapeutics (NASDAQ:RANI) announced positive topline results from the single-ascending dose (SAD) portion of its Phase 1 clinical study of its lead asset RT-102 for the potential treatment of osteoporosis. Rani Therapeutics shares traded in a range of $11.03 to $11.51 on a day volume of 13.93 thousand shares, closed regular trading session at $11.10. The company shares are currently trading at $10.75, down 3.2 percent in the after-hours trading session.